ggan

Gregory Gan, MD, PhD

Faculty Titles
Assistant Professor
Department of Internal Medicine
Division of Hematology/Oncology
Section of Radiation Oncology

UNM Cancer Center Position(s)
Director of Basic Research in Radiation Oncology

Cancer Specialty
Radiation Oncology

Multidisciplinary Team
Breast Cancers, Gastrointestinal Cancers, Gynecologic Cancers, Head and Neck Cancers, Lung/Esophagus Cancers, Neurological Cancers

Research Program
Cancer Therapeutics: Technology, Discovery and Targeted Delivery

NIH Biosketch
View Biosketch

Medical School
University of Pittsburgh School of Medicine (2009)

Graduate School
University of Pittsburgh SOM, Department of Pharmacology (2009)

Internship
UPMC Shadyside Hospital (2010)

Residency
University of Colorado Denver, Department of Radiation Oncology (2014)

Research Fellowship
University of Colorado Denver, Department of Radiation Oncology and Medical Oncology (2013 - 2014)

Expertise, Certifications and Memberships
Expertise: Head and neck, Thoracic, GI, Breast and Neuro Oncology; stereotactic body radiotherapy and radiosurgery; Phase I/II clinical trial development

Membership: ASTRO, AACR, RSNA

Personal Statement

I am a Radiation Oncologist and physician-scientist with a research interest in tumor microenvironment, epithelial-to-mesenchymal transition (EMT) and radiation biology. I am pursuing translational research with the goal of developing novel treatment strategies for head and neck, GI and lung cancers. We are testing the hypothesis that radiotherapy can up-regulate EMT which can lead to tumor repopulation, distant metastasis and overall treatment resistance. I am ideally suited to address this question because of my fellowship training and expertise in establishing head and neck cancer patient-derived tumor xenografts mouse models, developing a model for mouse head and neck irradiation, and evaluating tumor stem cell biology and its respective microenvironment.

I am also interested in how radiotherapy (particularly high dose per fraction also known as stereotactic body radiotherapy) and EMT may affect local and distant control rates in both HPV positive and negative head and neck cancers and thoracic malignancies. I became interested in this area because local control and overall survival remain very poor for patients with HPV negative head and neck cancers. Insights gained from a better understanding of why these tumors fail locally and distantly can potentially improve outcomes.

My overarching goals are to develop novel targeted agents which can synergize with radiation to improve outcomes not only in head and neck cancer patients but hopefully in other tumor types.